Drugs / AER-271
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03804476 | Jun 2018 → Jul 2019 | ischemic stroke | Aeromics, Inc. | Completed | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-12-09 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Aeromics and Simcere Announce the First-In-Human Dosing of Chinese Healthy Volunteers in Simcere's Phase I Study of The SIM0307 (AER-271), A New Drug for Brain Edema simcere.com ↗ |
| 2019-11-05 | Aeromics, Inc. | AEROMICS AND SIMCERE ANNOUNCE COLLABORATION AND LICENSE AGREEMENT FOR AER-271 IN GREATER CHINA aeromics.com ↗ |
| 2019-11-05 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Aeromics and Simcere Announce Collaboration and License Agreement for AER-271 in Greater China simcere.com ↗ |
| 2018-07-09 | Aeromics, Inc. | Aeromics Initiates Phase 1 Clinical Trial of CNS Edema Inhibitor AER-271 In Healthy Human Volunteers aeromics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AER-271 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03804476 ↗ |
| Action | Inhibit | “AER-271 is an Aquaporin-4 inhibitor designed to prevent brain swelling in severe ischemic stroke.” NCT03804476 ↗ |
| Route | Intravenous | “intravenously (IV) administered AER-271” NCT03804476 ↗ |